• Sachi Horibata, George Alyateem, Christin B DeStefano, and Michael M Gottesman.
• Laboratory of Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, United States.
• Curr Cancer Drug Targets. 2020 Jan 1; 20 (7): 532-544.

AbstractImproved understanding of the genomic and molecular landscape of acute myeloid leukemia (AML) has resulted in a significant evolution of our understanding of AML biology and allows refined prognostication for those receiving standard combination chemotherapy induction. This dramatic increase in knowledge preceded, and was somewhat responsible for, at least some of eight new FDA drug approvals for AML. This review discusses the impact of genomics on clinical care of AML patients and highlights newly approved FDA drugs. Despite these recent clinical advances, however, the outcome for most patients diagnosed with AML remains dire. Thus, we describe here some of the challenges identified with treating AML including off-target toxicity, drug transporters, clonal heterogeneity, and adaptive resistance, and some of the most promising opportunities for improved therapy.Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

28 keywords...

hide…